https://www.selleckchem.com/ph....armacological_epigen
Pembrolizumab is an established first-line option for patients with advanced non-small-cell lung cancer (NSCLC) expressing programmed death-ligand 1 ≥50%. Durable responses are seen in a subset of patients; however, many derive little clinical benefit. Biomarkers of the systemic inflammatory response predict survival in NSCLC. We evaluated their prognostic significance in patients receiving first-line pembrolizumab for advanced NSCLC. Patients treated with first-line pembrolizumab for advanced NSCLC with programmed death-liga
Like
Comment
Share
